NCT06971276Completed
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 104 (actual)
- First submitted
- 5 May 2025
- Start date
- Apr 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- NCT number
- NCT06971276
What you commit to
- Study type: Observational
- Participants enrolled: 104
- From Apr 2024 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not meeting inclusion criteria.
Who the study is looking for
- Past or current anal HPV-positive population undergone anal dysplasia screening.
- Control patients from the general population.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Infectious Diseases, Mass General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.